Thyroid disease:

Indications for TRIOSTAT:

Myxedema coma/precoma.


Give with glucocorticoids. Allow 4–12 hours between doses. Initially 25–50mcg. Cardiovascular disease: initially 10–20mcg. Usual range: 65–100mcg daily. Change to oral therapy as soon as possible: start tabs at low dose and increase gradually; discontinue IV gradually.


Not recommended.


Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis. Artificial rewarming.

Boxed Warning:

Not for treatment of obesity for weight loss.


Ineffective for weight reduction in euthyroid patients. Not for treatment of infertility. Cardiovascular disease, angina, elderly: initiate therapy at 10–20micrograms. Severe and prolonged hypothyroidism. Fluid therapy. Adrenocortical insufficiency. Pregnancy (Cat.A). Nursing mothers.

Pharmacologic Class:

T3 (synthetic).


Potentiates digitalis toxicity, tricyclic antidepressants, sympathomimetics (eg, anorectics). May increase risk of coronary insufficiency with vasopressors. Monitor oral anticoagulants, hypoglycemics. Estrogens affect thyroid function tests. May be potentiated by tricyclic antidepressants. Hypertension, tachycardia with ketamine.

Adverse Reactions:

Arrhythmia, tachycardia, cardiopulmonary arrest, hypotension, MI, angina, CHF, hypertension, twitching.

How Supplied:

Vials (1mL)—6